Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
Summary
NIH registered a Phase 2 clinical trial (NCT07540832) evaluating WGI-0301 in combination with Lenvatinib in patients with advanced hepatocellular carcinoma (HCC) at multiple hospital sites. The open-label study will assess safety, tolerability, pharmacokinetics, and early efficacy signals of the combination therapy.
What changed
NIH registered a new Phase 2 clinical trial for WGI-0301 combined with Lenvatinib for treatment of advanced hepatocellular carcinoma. The open-label, non-placebo study will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy signals at multiple hospital sites.
For clinical investigators, trial sponsors, and healthcare providers involved in oncology drug development, this represents an active Phase 2 study in the HCC treatment pipeline. The trial has no regulatory compliance implications at this stage and does not impose any obligations on regulated entities.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
Phase 1 NCT07540832 Kind: PHASE1 Apr 20, 2026
Abstract
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
Conditions: Advanced Hepatocellular Carcinoma (HCC)
Interventions: WGI-0301, WGI-0301, Lenvatinb
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.